Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure

Abstract

Travoprost is a prostaglandin analogue widely used for reducing intraocular pressure (IOP) in patients affected with glaucoma and ocular hypertension. It exerts its ocular hypotensive effect through the prostaglandin FP receptors, located in the ciliary muscle and the trabecular meshwork. Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle. When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues. The fixed combination of travoprost and timolol has demonstrated a hypotensive efficacy comparable to the concomitant administration of the two drugs. Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease. Low rates of topical and systemic adverse reactions, strong ocular hypotensive efficacy, and once-a-day dosing make travoprost a first-line treatment for patients affected with elevated IOP.

Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue

“…TTFC has been reported to have a neutral pH, which allows for the high permeability of the β component into the eye 17. Quaranta et al discussed the IOP-lowering effect of TTFC when switched from travoprost monotherapy in their review report 18,19. From their reports there is a possibility of greater IOP-lowering effect of TTFC when switched from travoprost than other FC when switched from each PGA.…”

Medical Management of Glaucoma in the 21st Century from a Canadian Perspective

“…PGAs have demonstrated better IOP-lowering ability than β -blockers with fewer systemic adverse effects [86–88]. They act by increasing uveoscleral and TM outflow and reduction in IOP starts 2–4 hours after first administration.…”

“…Several studies have shown that topical administration of travoprost leads to a mean IOP reduction from 25% to 32%, which is sustained throughout the 24-hour cycle [88, 89]. In a prospective, open-label, single-arm study conducted in Italy ( N = 36 previously untreated POAG patients), travoprost monotherapy at a dose of 0.004% administered once in the evening (8:00 pm) induced uniform 24-hour IOP reduction.…”

“…Although mean nocturnal IOP reduction with travoprost was somewhat lower than mean daytime IOP reduction, there was no significant difference between nighttime and daytime efficacy [89]. A preservative-free formulation of travoprost 0.004% is available to reduce tolerability-related problems in subjects affected with ocular surface disease [88]. …”

Ocular Surface and Glaucoma Drugs.

“…Using the impression citology, Sezgin Akcay et al 2014 found that polyquaternium (PP)-preserved travoprost is safer and better tolerated than benzalkonium chloride (BAK)-preserved travoprost. That's the reason why the compliance of patients increases (Quaranta 2015, Peace 2015. It may be an advantageous prostaglandin analog option for patients affected by open-angle glaucoma (OAG) or ocular hypertension (OHT) who are intolerant to BAK-preserved latanoprost or bimatoprost (Konstas et al 2017).…”